NCT03452332 - Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

August 11, 2023

Study Completion Date

August 11, 2023

Conditions

Advanced Cervical AdenocarcinomaAdvanced Vaginal CarcinomaAdvanced Vulvar CarcinomaHuman Papillomavirus-Related Cervical Squamous Cell CarcinomaHuman Papillomavirus-Related Vulvar Squamous Cell CarcinomaMetastatic Cervical AdenocarcinomaMetastatic Cervical CarcinomaMetastatic Cervical Squamous Cell Carcinoma, Not Otherwise SpecifiedMetastatic Vaginal AdenocarcinomaMetastatic Vaginal CarcinomaMetastatic Vulvar CarcinomaRecurrent Cervical AdenocarcinomaRecurrent Cervical CarcinomaRecurrent Cervical Squamous Cell Carcinoma, Not Otherwise SpecifiedRecurrent Vaginal CarcinomaRecurrent Vulvar CarcinomaStage III Cervical Cancer AJCC v8Stage III Vaginal Cancer AJCC v8Stage III Vulvar Cancer AJCC v8Stage IIIA Cervical Cancer AJCC v8Stage IIIA Vulvar Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8Stage IIIB Vulvar Cancer AJCC v8Stage IIIC Vulvar Cancer AJCC v8Stage IV Cervical Cancer AJCC v8Stage IV Vaginal Cancer AJCC v8Stage IV Vulvar Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8Stage IVA Vaginal Cancer AJCC v8Stage IVA Vulvar Cancer AJCC v8Stage IVB Cervical Cancer AJCC v8Stage IVB Vaginal Cancer AJCC v8Stage IVB Vulvar Cancer AJCC v8Vaginal Squamous Cell Carcinoma, Not Otherwise SpecifiedVulvar AdenocarcinomaVulvar Squamous Cell Carcinoma

Interventions

BIOLOGICAL

Durvalumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

RADIATION

Stereotactic Radiosurgery

Undergo SABR

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (2)

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER